Navigation Links
2005 was a tough year for U.S. biotech financing

As we are still in January, it is appropriate that we continue to review biotech results for 2005 and try to find lessons learned that might help us discern trends for 2006.

Another research tool I have always found useful for this analysis is Burrill & Co.'s financial tracking information on the biotech industry. On......

Full article >>> ded in Burrill's review, as Burrill focuses principally on drugs versus medical devices).

Another interesting trend that Burrill notes is M&A activities. We have all been filing the high profile bidding war in the beginning of 2006 (which actually started in 2005) between Boston Scientific/Abbott Labs and J&J to acquire Guidant; at this writing, it appears that Boston Scientific/Abbott La......

Full article >>> companies, struggling with their pipelines and potential generic intrusion as patents come to an end on key products.

Let's look at Burrill's information on the different channels of biotech financing in 2005:

U.S. biotech financing in 2005 ($millions)
Type of Financing20042005% Change
Public
Full article >>> n the U.S. Remember that this applies to a little more than the 300 publicly-traded biotech companies in the U.S.

VC financing of $3.5 billion in 2005 was down 7 percent. This result is bad news for the 1200+ privately held biotech companies in the U.S. that depend mostly on VC financing. Assuming the number of 1200 companies, the average raise-up per company was less than $3 million in ......

Full article >>> and early stage life science companies such as Renovar, a Wisconsin-based in-vitro diagnostics company. Rosen is also a founder and board member of the Illinois Biotechnology Industry Organization. He can be reached at rosenmichaels@aol.com

This article has been syndicated on the Wisconsin Technology Netw......

Full article >>>
'"/>

Source:wistechnology.com By Michael Rosen 01/30/06


Related biology technology :

1. The tough choices facing health care
2. Venture-backed companies drive job creation, even in tough times
3. Vertical partnering: Street smarts for a tough marketplace
4. The state of global biotech: An Ernst & Young perspective
5. Olympics of biotechnology has international flavor
6. Getting noticed in Genetown: Wisconsin biotech on display
7. Madison biotech NimbleGen files for IPO; one of states best-funded firms
8. Wisconsin biotech firm receives $107K NIH grant
9. Manufacturing partnership will move into biotech and biomedical spaces
10. Wisconsin wont get Georgia biotech without a fight
11. The 10 biggest events shaping biotech in 2006
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/20/2017)... ORLANDO, Fla. , Feb. 20, 2017 /PRNewswire/ ... (HIMSS) conference in Orlando , ... new offerings, collaborators and clients. IBM Chairman, President ... the HIMSS17 opening keynote address today from 8:30-10 ... www.ibm.com/watson/health , and ibm.com/industries/healthcare. Her remarks examine ...
(Date:2/18/2017)... MONTREAL , February 18, 2017 ... von intrazellulären Zytokinen bei adoptiven Zelltherapie-Studien, Poster legt metaproteomische ... ... Biosciences Inc. heute bekanntgab, wird Dr. Yoav Peretz ... Methoden in der Entwicklung von Assays zum Nachweis intrazellulärer ...
(Date:2/18/2017)... Research and Markets has announced the addition of the ... offering. ... report provides separate comprehensive analytics for the US, Japan ... Annual estimates and forecasts are provided for the period 2015 through ... Market data and analytics are derived from primary and secondary research. ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
Breaking Biology Technology:
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):